Statistical integration of multi-omics and drug screening data from cell lines
Authors: el Bouhaddani Said , Höllerhage Matthias , Uh Hae-Won , Moebius Claudia , Bickle Marc , Höglinger Günter , Houwing-Duistermaat Jeanine 
Published: August 2022

AbstractData integration methods are used to obtain a unified summary of multiple datasets. For multi-modal data, we propose a computational workflow to jointly analyze datasets from cell lines. The workflow comprises a novel probabilistic data integration method, named POPLS-DA, for omics data.The workflow is motivated by a study on synucleinopathies where transcriptomics, proteomics, and drug screening data are measured in affected LUHMES cell lines and controls. The aim is to highlight potentially druggable pathways and genes involved in synucleinopathies. First, POPLS-DA is used to prioritize genes and proteins that best distinguish cases and controls. For these genes an integrated interaction network is constructed, where the drug screen data is incorporated to highlight druggable genes and pathways in the network. Finally functional enrichment analyses are performed to identify clusters of synaptic and lysosome-related genes and proteins targeted by the protective drugs.We found thatHSPA5, a member of the heat shock protein 70 family, was one of the most targeted genes by the validated drugs, in particular by AT1-blockers.HSPA5and AT1-blockers have been previously linked toα-synuclein pathology and Parkinson’s disease, showing the relevance of our findings.Our computational workflow identified new directions for therapeutic targets for synucleinopathies. An implementation based on R and markdown is freely available online.Author summaryWe present a computational workflow that combines the analysis of different types of data measured in cell line studies with non-overlapping samples. We apply the workflow to measurements of gene expression, protein abundances, and a screening of a wide range of FDA-approved drugs. These different types of data are obtained from LUHMES brain cells and jointly analyzed to discover new treatment options in synucleinopathies, such as Parkinson’s disease. Our workflow includes a new probabilistic method, named POPLS-DA. POPLS-DA combines the analysis of the genes and proteins to pinpoint a set of relevant genes and proteins that can distinguish affected and non-affected cells. Furthermore, we constructed a network that connects together the relevant genes and proteins that interact with each other. We incorporate the drug screening data to highlights which part of the network is relevant to the disease and druggable. Through additional analysis of the functionality, we discovered that the genes and proteins that are targeted by protective drugs share relevant properties, namely they are synaptic and lysosome related genes. Notably, we found that a specific type of drugs, namely AT1-blockers such as Telmisartan, are protective and target the network of relevant genes and proteins. These drugs are approved by the FDA and readily available to further investigate its potential in treating synucleinopathies. We further found that a gene named HSPA5, a member of the heat shock protein 70 family, is highly targeted by the protective drugs. This gene has been linked to Parkinson’s disease in previous scientific literature. Our computational workflow and the implementation in R and markdown are freely available online.